Clinical Trial Update: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating avelumab plus intermittent axitinib in previously untreated metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Axitinib (Axitinib)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Renal Carcinoma Metastatic | Phase 2 | Status: UNKNOWN